- Limited direct evidence: No high-quality human trials have tested melatonin specifically as an appetite-control aid; most relevant data comes from animal studies or secondary observations in metabolic research.
- Indirect links exist: Melatonin may influence hunger-related hormones (leptin, ghrelin, insulin) in ways that could affect appetite, but the effect in humans is small and inconsistent.
- Sleep improvement is the more credible pathway: If melatonin helps you sleep better, and poor sleep is driving your overeating, there may be a modest indirect benefit — but the supplement itself is not an appetite suppressant.
- Honest bottom line: Melatonin is not a meaningful tool for appetite control; targeting sleep hygiene broadly is a better-evidenced strategy.
What the evidence shows
The direct evidence for melatonin as an appetite-control supplement in humans is thin. A PubMed search turns up no large, well-controlled randomized trials with appetite suppression as a primary endpoint. What exists is a patchwork of smaller studies, animal data, and secondary measurements — which is worth walking through honestly.
In rodent models, melatonin supplementation has repeatedly been associated with reductions in body weight, visceral fat, and improved insulin sensitivity (Favero et al., 2017). Rodents are nocturnal, however, and their melatonin rhythms differ substantially from ours, making direct translation unreliable.
In human metabolic studies, the picture is mixed. A 2013 randomized trial of postmenopausal women found that one year of nightly melatonin (1–3 mg) was associated with small but statistically significant reductions in fat mass and a modest increase in lean mass compared with placebo, alongside changes in adipokines including leptin (Amstrup et al., 2016 — note: this trial was primarily studying bone density, and body composition was a secondary outcome). The appetite implications of these hormonal shifts were not directly tested.
On the hunger-hormone side, some research suggests melatonin may modestly raise leptin (a satiety hormone) or blunt the overnight rise in ghrelin (a hunger hormone), but study samples are small and results are not consistent across populations (Walecka-Kapica et al., 2015).
One area with slightly more signal is binge-eating and night-eating syndrome. A small pilot study found that melatonin reduced nighttime eating and subjective hunger ratings in patients with night-eating syndrome (Goel et al., 2009). This is intriguing but far from confirmatory — it involved a narrow population and a very short follow-up.
For the general person asking "will melatonin help me eat less?", the honest answer is: the existing literature does not support that conclusion.
How it works (mechanism)
Melatonin is a hormone produced by the pineal gland in response to darkness; it signals the body that night has arrived and helps coordinate circadian rhythms. Its potential connection to appetite runs through several pathways:
- Circadian regulation of hunger hormones: Ghrelin and leptin both follow daily rhythms tied to the sleep-wake cycle. Melatonin helps anchor those rhythms; chronic disruption (shift work, poor sleep) raises ghrelin and lowers leptin, increasing hunger (Taheri et al., 2004).
- Insulin and adipose signaling: Melatonin receptors (MT1 and MT2) are found in the pancreas and adipose tissue. Animal studies suggest melatonin improves insulin sensitivity and may reduce fat-cell inflammation, both of which interact with appetite regulation (Cipolla-Neto et al., 2014).
- Sleep quality: Improving sleep duration and quality is independently associated with lower caloric intake and better appetite-hormone balance (Hanlon & Van Cauter, 2011). If melatonin improves your sleep, it may help appetite indirectly — but this is a sleep benefit, not a pharmacological appetite effect.
None of these mechanisms have been convincingly shown to translate into clinically meaningful appetite suppression in healthy adults taking an over-the-counter melatonin supplement.
Dose & timing if you try it
If you have documented sleep-onset difficulty and want to address poor sleep as part of a weight-management strategy, the evidence-based approach to melatonin dosing is:
- Dose: 0.5–3 mg. Higher doses (5–10 mg) commonly sold in the US are above what most sleep researchers consider necessary and may cause next-day grogginess (Zhdanova et al., 2001). Bigger is not better with melatonin.
- Timing: 30–60 minutes before your target bedtime. Taking it too early or too late can shift your circadian phase in the wrong direction.
- Duration: Short-term use (days to a few weeks) for resetting sleep patterns is better studied than indefinite nightly use.
- Expectation setting: Take it for sleep, not for appetite. If sleep improves and you notice less nighttime snacking, that is likely the sleep benefit at work.
Who should skip
- Pregnant or breastfeeding individuals: Safety data in these populations is insufficient; melatonin crosses the placenta and appears in breast milk. Avoid unless specifically directed by an OB or midwife.
- Children and adolescents: Developing circadian systems may be sensitive to exogenous melatonin; use only under pediatric supervision.
- People on anticoagulants (e.g., warfarin): Melatonin may have additive effects and alter bleeding time.
- People taking immunosuppressants or seizure medications: Melatonin has immunomodulatory and potential CNS effects that can interact with these drug classes.
- People with autoimmune conditions: Melatonin's immune-stimulating properties could theoretically worsen autoimmune activity.
- People with diabetes on insulin or oral hypoglycemics: Given its effects on insulin signaling, glucose monitoring should be tightened if melatonin is started.
Bottom line
Melatonin is not an appetite suppressant. The evidence for using it specifically to control hunger or reduce caloric intake in humans is weak, indirect, and largely extrapolated from animal data or small studies in narrow populations. If poor sleep is undermining your appetite regulation — a genuinely well-evidenced problem (Taheri et al., 2004; Hanlon & Van Cauter, 2011) — then addressing sleep is worthwhile, and low-dose melatonin is a reasonable, low-risk tool for that. But framing it as a weight-loss or appetite-control supplement overstates what the science actually shows. Save your money and your expectations for interventions with stronger direct evidence.
References
- Amstrup, A.K., Sikjaer, T., Pedersen, S.B., et al. (2016). Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women. Clinical Endocrinology, 84(3), 342–347.
- Cipolla-Neto, J., Amaral, F.G., Afeche, S.C., et al. (2014). Melatonin, energy metabolism, and obesity. Journal of Pineal Research, 56(4), 371–381.
- Favero, G., Moretti, E., Valle, M., et al. (2017). Obese mouse adipose index, metabolic parameters, and cardiovascular system amelioration: role of melatonin treatment. Journal of Pineal Research, 63(2), e12410.
- Goel, N., Stunkard, A.J., Rogers, N.L., et al. (2009). Circadian rhythm profiles in women with night eating syndrome. Journal of Biological Rhythms, 24(1), 85–94.
- Hanlon, E.C., & Van Cauter, E. (2011). Quantification of sleep behavior and of its impact on the cross-talk between the brain and peripheral metabolism. Proceedings of the National Academy of Sciences, 108(Suppl 3), 15609–15616.
- Taheri, S., Lin, L., Austin, D., et al. (2004). Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLOS Medicine, 1(3), e62.
- Walecka-Kapica, E., Chojnacki, J., Stępień, A., et al. (2015). Melatonin and female hormone secretion in postmenopausal overweight women. International Journal of Molecular Sciences, 16(1), 1030–1042.
- Zhdanova, I.V., Wurtman, R.J., Regan, M.M., et al. (2001). Melatonin treatment for age-related insomnia. Journal of Clinical Endocrinology & Metabolism, 86(10), 4727–4730.